Meanwhile, if you buy the shares while they're down, you will have gotten in on the stock for a bargain -- and can maximize ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...

Moderna’s COVID-19 vaccine has received full FDA approval for use in children at higher risk for severe illness.

J.P. Morgan’s U.S. equity research analysts compiled their list of “most compelling structural and tactical short ideas” for ...

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

The average short interest for the S&P 500 Health Care Index Sector (NYSEARCA:XLV) experienced an increase in June, moving ...

Moderna is expected to announce its second-quarter results in the upcoming month, and analysts expect a slight reduction in ...

If approved in the world's biggest pharmaceuticals market, GSK's vaccine, Arexvy, would be competing for a market share in ...